Pulse Biosciences Future Growth
Future criteria checks 2/6
Pulse Biosciences is forecast to grow earnings and revenue by 21.7% and 63.9% per annum respectively while EPS is expected to grow by 22.8% per annum.
Key information
21.7%
Earnings growth rate
22.80%
EPS growth rate
| Medical Equipment earnings growth | 16.9% |
| Revenue growth rate | 63.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 09 Sep 2026 |
Recent future growth updates
Recent updates
Narrative Update • Sep 09
PLSE: Pivotal nsPFA Trials And Early Data Will Drive Bullish Outlook
Analysts have revised their fair value estimate for Pulse Biosciences to $58 from $35, citing growing confidence in the company's differentiated nanosecond pulse field ablation platform, positive early clinical signals, and the potential impact of ongoing pivotal studies and future partnerships. Analyst Commentary on Pulse Biosciences Recent Street research on Pulse Biosciences has taken a more constructive tone, with several bullish analysts highlighting the company’s nanosecond pulsed field ablation platform and early clinical data as key supports for their valuation work.
Narrative Update • Aug 26
PLSE: Pivotal Nanosecond Ablation Data And Partnerships Will Shape 3b Market Access
Analysts have lifted the fair value estimate for Pulse Biosciences to $45.25 from $41, citing Street research that highlights its differentiated nanosecond pulsed field ablation platform, positive early clinical data, progress in pivotal studies, and what they view as improving success probabilities following recent updates. Analyst Commentary Recent Street research on Pulse Biosciences centers on the potential of its nanosecond pulsed field ablation platform, the pace of clinical development, and how these factors feed into valuation and execution risk for investors following the story into late 2026.Narrative Update • Aug 12
PLSE: Clinical And Regulatory Progress Will Test Access To 3b Ablation Market
The analyst price target for Pulse Biosciences has been reset from about $30.67 to $41.00, with analysts pointing to improving success probabilities for its nanosecond pulsed field ablation platform and continued clinical and regulatory progress as key drivers of their updated views. Analyst Commentary Recent Street research on Pulse Biosciences highlights both optimism around the nanosecond pulsed field ablation platform and a focus on the execution risks that come with an early stage commercial story.
New Narrative • Aug 07
Slower Pulsed Field Ablation Adoption Will Limit Revenue Scale And Delay Profitability
Catalysts About Pulse Biosciences Pulse Biosciences develops medical devices based on nanosecond pulsed field ablation technology for cardiac and thyroid procedures. What are the underlying business or industry changes driving this perspective?Narrative Update • Jul 29
PLSE: Cardiac Ablation Data And Index Inclusion Will Guide Fairly Valued Outlook
Analysts have lifted their price target on Pulse Biosciences to $35 from $30, citing preliminary support for the nsPFA platform's safety and efficacy profile in cardiac ablation and its potential to address a large electrophysiology market opportunity. Analyst Commentary on Pulse Biosciences Recent Street research on Pulse Biosciences points to growing confidence in the potential of its nanosecond pulsed field ablation, or nsPFA, platform in cardiac ablation.Narrative Update • Jul 10
PLSE: Ablation Platform And Clinical Data Will Drive Access To 3b Market
Analysts have lifted the fair value estimate for Pulse Biosciences from about $22 to roughly $30.67 per share, citing the company’s differentiated nanosecond pulsed field ablation platform and the roughly $3 billion electrophysiologists ablation market opportunity as key drivers behind a Street price target of $32. Analyst Commentary Recent Street research on Pulse Biosciences centers on the potential of its nanosecond pulsed field ablation platform and how that might justify the latest fair value estimate and price targets around US$32 per share.Narrative Update • Jun 26
PLSE: Nanosecond Cardiac Ablation Platform Will Pursue Expanding Electrophysiology Opportunity
Analysts raised their price target on Pulse Biosciences stock from $30 to $32, citing its differentiated nanosecond pulsed field cardiac ablation platform and the $3 billion electrophysiology ablation market, which they estimate is growing 10% to 15% annually, with potential for the company to capture a meaningful share. Analyst Commentary Bullish analysts covering Pulse Biosciences emphasize that the stock is now being valued around a clearly defined opportunity in cardiac ablation, supported by a specific US$32 price target.New Narrative • Feb 09
Early Thyroid And Cardiac Applications Will Establish A Powerful Medical Device Platform
Catalysts About Pulse Biosciences Pulse Biosciences develops and commercializes medical devices that use proprietary nanosecond pulse field ablation technology for soft tissue and cardiac applications. What are the underlying business or industry changes driving this perspective?Analysis Article • Dec 21
Pulse Biosciences (NASDAQ:PLSE) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • Jun 12
Here's Why We're Not At All Concerned With Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Analysis Article • Feb 07
We're Not Very Worried About Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Pulse...Seeking Alpha • May 16
Pulse Biosciences Stock: Signs Of Life Following Q1 Update
Summary We recap Q1 developments from Pulse Biosciences, Inc. The FDA has cleared the company's percutaneous electrode system, while the surgical clamp device for cardiac indications is still in the preclinical trial phase. Pulse Biosciences is making progress in its commercialization strategy, but financial uncertainties may keep the stock under pressure. Read the full article on Seeking AlphaAnalysis Article • May 10
We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysis Article • Dec 25
We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Pulse Biosciences...Analysis Article • Sep 04
We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 19 | -88 | -67 | -67 | 3 |
| 12/31/2027 | 7 | -102 | -77 | -80 | 5 |
| 12/31/2026 | 2 | -96 | -71 | -73 | 4 |
| 6/30/2026 | 1 | -80 | -61 | -61 | N/A |
| 3/31/2026 | 1 | -75 | -56 | -55 | N/A |
| 12/31/2025 | 0 | -73 | -54 | -54 | N/A |
| 9/30/2025 | 0 | -75 | -49 | -49 | N/A |
| 6/30/2025 | N/A | -68 | -45 | -44 | N/A |
| 3/31/2025 | N/A | -60 | -40 | -40 | N/A |
| 12/31/2024 | N/A | -54 | -36 | -36 | N/A |
| 9/30/2024 | N/A | -46 | -34 | -34 | N/A |
| 6/30/2024 | N/A | -44 | -36 | -35 | N/A |
| 3/31/2024 | N/A | -43 | -36 | -36 | N/A |
| 12/31/2023 | N/A | -42 | -33 | -33 | N/A |
| 9/30/2023 | 0 | -39 | -34 | -34 | N/A |
| 6/30/2023 | 0 | -47 | -35 | -34 | N/A |
| 3/31/2023 | 0 | -51 | -38 | -38 | N/A |
| 12/31/2022 | 1 | -59 | -47 | -47 | N/A |
| 9/30/2022 | 2 | -65 | -52 | -52 | N/A |
| 6/30/2022 | 2 | -61 | -55 | -54 | N/A |
| 3/31/2022 | 2 | -62 | -59 | -58 | N/A |
| 12/31/2021 | 1 | -64 | -55 | -54 | N/A |
| 9/30/2021 | 1 | -62 | -51 | -51 | N/A |
| 6/30/2021 | N/A | -61 | -46 | -46 | N/A |
| 3/31/2021 | N/A | -57 | -38 | -37 | N/A |
| 12/31/2020 | N/A | -50 | -36 | -35 | N/A |
| 9/30/2020 | N/A | -50 | -35 | -35 | N/A |
| 6/30/2020 | N/A | -49 | -35 | -35 | N/A |
| 3/31/2020 | N/A | -49 | N/A | -36 | N/A |
| 12/31/2019 | N/A | -47 | N/A | -34 | N/A |
| 9/30/2019 | N/A | -42 | N/A | -31 | N/A |
| 6/30/2019 | N/A | -41 | N/A | -30 | N/A |
| 3/31/2019 | N/A | -39 | N/A | -26 | N/A |
| 12/31/2018 | N/A | -38 | N/A | -24 | N/A |
| 9/30/2018 | N/A | -37 | N/A | -22 | N/A |
| 6/30/2018 | N/A | -34 | N/A | -18 | N/A |
| 3/31/2018 | N/A | -31 | N/A | -14 | N/A |
| 12/31/2017 | N/A | -26 | N/A | -11 | N/A |
| 9/30/2017 | N/A | -20 | N/A | -9 | N/A |
| 6/30/2017 | N/A | -15 | N/A | -8 | N/A |
| 3/31/2017 | N/A | -11 | N/A | -9 | N/A |
| 12/31/2016 | N/A | -10 | N/A | -8 | N/A |
| 9/30/2016 | N/A | -8 | N/A | -7 | N/A |
| 6/30/2016 | N/A | -6 | N/A | -6 | N/A |
| 3/31/2016 | N/A | -4 | N/A | -4 | N/A |
| 12/31/2015 | N/A | -3 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PLSE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PLSE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PLSE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PLSE's revenue (63.9% per year) is forecast to grow faster than the US market (13.6% per year).
High Growth Revenue: PLSE's revenue (63.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PLSE's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 17:40 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pulse Biosciences, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Plovanic | Canaccord Genuity |
| Keith Hinton | Freedom Capital Markets |
| Anthony Petrone | Mizuho Securities USA LLC |